Akums Drugs and Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Haridwar, Uttarakhand. Founded in 2004 by Sanjeev Jain and Sandeep Jain, the company serves domestic pharmaceutical businesses as well as multinational customers. Its principal role in the pharmaceutical value chain is to develop and manufacture finished dosage forms for other companies, rather than relying exclusively on a consumer-facing portfolio of proprietary brands. The company's capabilities span formulation development, technology transfer, commercial production, quality-control support, packaging, and related pharmaceutical manufacturing services. Its portfolio includes tablets, hard-gelatin capsules, soft gels, dry syrups, liquid oral medicines, topical products, and parenteral products such as vials, ampoules, eye drops, and form-fill-seal presentations. Akums also operates facilities for active pharmaceutical ingredient production and research and development centers in India. These capabilities allow it to support customer projects across development, scale-up, regulatory manufacturing, and supply. Akums has built a manufacturing network comprising multiple formulation plants and two API facilities. Some Haridwar units have obtained international GMP certifications, supporting the company's stated objective of serving regulated and export markets. The company has also pursued product and intellectual-property development, including a manufacturing and commercialization licence for bempedoic acid, a patent relating to an extended-release doxylamine and pyridoxine combination, and a patent for a dual-release gastro-resistant composition. In 2026, it received United Kingdom regulatory approval to market rivaroxaban, an anticoagulant. The business expanded through both organic development and transactions. In 2020, Quadria Capital invested Rs 500 crore in the company. In April 2022, Akums acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited. These developments strengthened its production footprint and supported its transition toward a larger, more diversified CDMO platform. Akums became a publicly traded company on 6 August 2024, with shares listed on the Bombay Stock Exchange and the National Stock Exchange of India. Public-company status increased the amount of information available about its operations and strategic activity, although detailed customer-level revenue, product-level sales, and complete geographic revenue data should be verified through current company filings and exchange disclosures. Its present positioning is that of an Indian, multi-dosage-form pharmaceutical manufacturing partner with domestic scale, development capabilities, and growing access to regulated international markets.

Akums Drugs and Pharmaceuticals was established in 2004 by Sanjeev Jain and Sandeep Jain in India. Both founders are identified as managing directors, and the company developed around pharmaceutical manufacturing and contract supply rather than a single consumer-oriented medicine brand. Over time, it expanded into a broader contract development and manufacturing organization, serving Indian pharmaceutical companies and multinational customers. Its operating model combines formulation development with production of finished pharmaceutical products. Akums' manufacturing activities cover oral solid forms such as tablets and capsules, soft gels, dry syrups, liquid oral medicines, topical preparations, and sterile or other parenteral presentations. The company also has two facilities for active pharmaceutical ingredients and four research and development centers in India. This combination of development, API, dosage-form, and packaging capabilities reflects the increasing outsourcing of pharmaceutical production to specialized Indian manufacturers. The company received a reported Rs 500 crore investment from Quadria Capital in 2020. In April 2022, it acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited. During the same year, it obtained a licence to manufacture and commercialize bempedoic acid. Its regulatory reach also broadened when two Haridwar units received European GMP certification: one for solid oral products, including tablets and hard-gelatin capsules, and another for large- and small-volume parenterals, including vials, ampoules, eye drops, and form-fill-seal products. Akums entered the Indian public markets on 6 August 2024, when it became listed on the Bombay Stock Exchange and the National Stock Exchange. Listing marked a significant change in its corporate profile, providing public-market access and subjecting the company to continuing exchange and regulatory disclosure requirements. In 2025, the company continued developing its intellectual-property and international-compliance position. It received a patent for an extended-release combination of doxylamine and pyridoxine for the management of nausea and vomiting in pregnancy. It also obtained a 20-year patent for a dual-release gastro-resistant composition, with the patent effective from 19 November 2022. During July and September, facilities in Haridwar received additional GMP certifications, including certification connected with Brazil's health regulator and the Eurasian Economic Union for a hormonal-therapy unit. In January 2026, two Haridwar facilities received European Union GMP certification from the Bulgarian Drug Agency. The following month, Akums received approval from the UK's Medicines and Healthcare products Regulatory Agency to market rivaroxaban. These certifications and approvals indicate an effort to extend the company's manufacturing and product-access capabilities beyond India. Public sources do not establish a complete chronology of every plant expansion, customer contract, product registration, or financial result; those matters require confirmation from current corporate filings and regulator records.

• 2026

  European Union GMP certification

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Two Haridwar facilities received EU GMP certification issued by the Bulgarian Drug Agency.

• 2026

  UK rivaroxaban approval

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  The UK MHRA approved Akums to market rivaroxaban in the United Kingdom.

• 2025

  Doxylamine-pyridoxine patent

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Akums received a patent for an extended-release combination formulation of doxylamine and pyridoxine.

• 2025

  Dual-release composition patent

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  The company received a 20-year patent for a dual-release gastro-resistant composition.

• 2024

  Public listing

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Akums became publicly listed on the Bombay Stock Exchange and the National Stock Exchange on 6 August.

• 2022

  Manufacturing facility acquisition

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Akums acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited.

• 2022

  Bempedoic acid licence

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  The company received authorization to manufacture and commercialize bempedoic acid.

• 2020

  Quadria Capital investment

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Quadria Capital invested a reported Rs 500 crore in Akums.

• 2004

  Company established

  [1]Akums Drugs and Pharmaceuticalsen.wikipedia.org

  Sanjeev Jain and Sandeep Jain established Akums Drugs and Pharmaceuticals in India.

Indian multi-dosage-form pharmaceutical CDMO and finished-drug manufacturer serving domestic and multinational pharmaceutical companies.

• Finished pharmaceutical dosage form

  Tablets

  Tablets are a major oral-solid dosage form manufactured by Akums for its own production activities and customer programs. The company's support can include formulation development, process scale-up, commercial manufacture, testing, and packaging. Individual active ingredients, brands, and therapeutic applications vary by customer and regulatory market.

• Finished pharmaceutical dosage form

  Hard-gelatin capsules

  Hard-gelatin capsules form part of Akums' oral-solid manufacturing capabilities. They can be produced under contract for pharmaceutical companies that outsource formulation and finished-dose manufacturing. Akums has identified a European-GMP-certified unit associated with solid oral products, including capsules.

• Finished pharmaceutical dosage form

  Soft gels

  Soft gels are among the dosage forms included in Akums' pharmaceutical production portfolio. They are typically used for formulations requiring encapsulation of liquid or semi-solid fills. Specific products and customer brands are not fully identified in the available reference material.

• Finished pharmaceutical dosage form

  Dry syrups

  Dry syrups are powdered or granulated medicines intended for reconstitution before administration. Akums manufactures this dosage form as part of its contract and finished-pharmaceutical activities, with formulation, production, testing, and packaging determined by the relevant customer and product registration.

• Finished pharmaceutical dosage form

  Liquid oral formulations

  Liquid oral products, including oral solutions and syrups, are part of Akums' multi-dosage-form manufacturing range. These products support customers that need non-solid presentations and may require specialized filling, stability testing, and packaging. The available sources do not specify a single flagship liquid formulation.

• Sterile and injectable pharmaceutical products

  Parenteral products

  Akums' parenteral capabilities include large- and small-volume products such as vials, ampoules, eye drops, and form-fill-seal formulations. A Haridwar unit associated with these products received European GMP certification, supporting manufacture for markets with regulated quality requirements.

• Pharmaceutical raw materials

  Active pharmaceutical ingredients

  Akums operates two facilities for producing active pharmaceutical ingredients. API manufacturing complements its finished-dose and CDMO operations by adding upstream production capability, although the available reference does not provide a complete list of APIs or identify the proportion of revenue generated by this activity.

• Anticoagulant medicine · 2026

  Rivaroxaban

  Rivaroxaban is an anticoagulant that Akums received UK MHRA approval to market in February 2026. The available material identifies the regulatory authorization but does not specify the product's brand name, commercial launch date, dosage presentation, or financial contribution.

• 2026

  Obtain UK authorization for rivaroxabanProduct launch

  Background

  Akums was expanding its access to regulated international pharmaceutical markets.

  Action taken

  The UK MHRA approved the company to market rivaroxaban in the United Kingdom.

  Aftermath

  The approval created a regulatory pathway for UK commercialization of the anticoagulant, although the launch timing and commercial scale are not specified.

  Source

• 2024

  Enter the public marketsStrategy

  Background

  Akums had expanded into a multi-facility pharmaceutical manufacturing and CDMO business and sought public-market access.

  Action taken

  The company completed its public listing on 6 August 2024 on the Bombay Stock Exchange and the National Stock Exchange of India.

  Aftermath

  Akums became a publicly traded pharmaceutical company subject to ongoing exchange and regulatory disclosure requirements.

  Source

• 2022

  Acquire a manufacturing facility from Ankur DrugsM&A

  Background

  Akums sought to expand its pharmaceutical manufacturing footprint and production capacity.

  Action taken

  The company acquired a manufacturing facility from Ankur Drugs and Pharmaceuticals Limited in April 2022.

  Aftermath

  The transaction added manufacturing infrastructure to Akums' broader CDMO and finished-dose platform; detailed capacity and financial effects are not specified in the available source.

  Source

1. 1Akums Drugs and Pharmaceuticalsen.wikipedia.org